Log in with your email address username.


Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Comment] New regulations to cut valproate-exposed pregnancies

In 1948, as the UK’s National Health Service (NHS) was born, “neurological” treatments consisted of antibiotics, B12 injections, and phenobarbital or phenytoin.1 Much has changed. In epilepsy alone, there are now about 26 anti-epileptic drugs (AEDs). Through much of this transformation, an AED has provided both hope and concern: valproate. Initially licensed for epilepsy in France in 1967,2 valproate is an effective AED recommended in England by the National Institute for Health and Care Excellence (NICE) as a first-line agent for generalised or unspecified epilepsy and second-line for focal epilepsy.